Document:

Exhibit 10.8

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This Employment Agreement ("Agreement")
is effective on November 26, 2018 (the “Effective Date”) between Item 9 Labs Corp., a Delaware corporation ("Company")
and Sara Gullickson ("Executive"). The Company and Executive are sometimes referred to herein individually as
a “Party” and collectively as the “Parties.”

 

RECITALS:

 

WHEREAS, the Company,
by and through its wholly owned subsidiary AZ DP Holdings, LLC (“AZDP”), acquired the Purchased Assets of Arizona
DP Consulting LLC, an Arizona limited liability company (“ADP”), pursuant to that certain Asset Purchase Agreement
of even date herewith by and between the Company, AZDP, ADP, and Executive as sole owner of ADP, incorporated herein by reference
(the “Asset Purchase Agreement”).

 

WHEREAS, any terms
not herein defined shall have the same meaning as set forth in the Asset Purchase Agreement.

 

WHEREAS, the Company
is a publicly traded corporation engaged in the business of cultivating quality-driven cannabis flower and marijuana products in
Arizona and Nevada (the “Business”) and following the Closing of the Asset Purchase Agreement, the Company will
own and operate the Purchased Assets by and through AZDP.

 

WHEREAS, the Executive
is in the business of providing the kinds of services required in the Company’s Business and has extensive experience in
operating the business related to the Purchased Assets.

 

WHEREAS, the Company
desires that Executive be employed by the Company, and render services to the Company, and Executive is willing to be so employed
and to render such services to the Company, all upon the terms and subject to the conditions contained herein.

 

NOW, THEREFORE,
in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

AGREEMENT:

 

1. EMPLOYMENT.  Subject
to and upon the terms and conditions contained in this Agreement, the Company hereby agrees to employ Executive and Executive
agrees to be employed by the Company, for the period set forth in paragraph 2 hereof, to render to the Company, its
affiliates and/or subsidiaries the services described in paragraph 3 hereof.

 

The Executive hereby acknowledges
and agrees that upon the Effective Date, any and all existing employment or consulting agreements entered into between Company
and Executive are hereby expressly terminated and replaced in entirety by this Agreement.

 

2. TERM.  Executive’s
employment under this Agreement shall commence as of the Effective Date hereof and shall continue for a period of three (3)
years unless earlier terminated by the Board of Directors (the “Board”) of the Company or by the Executive
in accordance with the terms of this Agreement (the “Employment Term”).

 

3. DUTIES.

 

(a)
Executive shall serve as the Chief Executive Officer of the Company, reporting directly to
the Board and shall be responsible for the management and running of the day-to-day operations of the Company, including, but not
limited to, those services set forth in Exhibit A, attached hereto and incorporated herein by reference (the “Services”).

 

(b)
Executive shall perform all duties and services incidental to the positions held by her. The
Board retains the right to change Executive's duties and reporting relationships as may be determined to be in the best interests
of the Company; provided, however, that any such change in Executive's duties shall be consistent with Executive's training, experience,
and qualifications.

 

(c)
Executive shall serve as a member of the Board of the Company during the Employment Term.

 

(d)
Executive agrees to abide by all bylaws and policies of the Company promulgated from time
to time by the Company and made available to Executive as well as all laws, statutes and regulations in all material respects.

 

4. BEST
EFFORTS.  Executive agrees to devote her full business time and attention, subject to absences for
customary vacations and for temporary illness, as well as her best efforts, energies and skill, to faithfully and
industriously perform the duties and responsibilities attributable to her position, to the reasonable satisfaction of the
Company. In addition, Executive will not engage in any other gainful occupation which requires Executive’s personal
attention and/or creates a conflict of interest with job responsibilities under this Agreement without the prior approval of
the Board, with the exception that Executive may personally trade in stock, bonds, securities, commodities or real estate
investments for her own benefit. Company hereby grants express permission to Executive to continue operating the existing
business ventures as set forth in Exhibit B attached hereto and incorporated herein by reference, so long as such
obligations do not materially interfere with Executives performance of the Services.

 

5. COMPENSATION.
The Company will pay Executive the following compensation for her services under this Agreement:

 

(a) Base
Salary. As compensation for her services and covenants hereunder, the Parties mutually agree that the Company shall
pay executive an annual salary of $200,000 USD per annum, payable in accordance with the Company’s normal payroll
methods (the “Base Salary”). The Base Salary will be reviewed from time to time in accordance with the
established procedures of the Company for adjusting salaries for similarly situated executives and may be adjusted upwards in
the sole discretion of the Company.

 

(b) Performance
Bonus. Executive is eligible to receive a discretionary annual bonus in an amount up to 100% of Executives Base
Salary, to be determined in the sole and absolute discretion of the Board, payable in cash, based upon the Company’s
operating results and gross sales, or such other performance benchmarks as determined by the Board (“Performance
Bonus”), with the criteria for eligibility to receive such Performance Bonus to be provided to Executive at the
beginning of each year of the Employment Term. 

 

(c) Incentive
Plan. Executive shall also be eligible to participate in the Company’s annual incentive plan for
executives (“Incentive Bonus”), if applicable. The criteria for determining the amount of the Incentive
Bonus, and the conditions that must be satisfied to entitle Executive to receive the Incentive Bonus for any year during the
Employment Term of this Agreement shall be determined by the Board or its compensation committee and provided to Executive at
the beginning of such year. 

 

6. EXPENSES.  

 

(a) Reimbursement.
Executive shall receive a Company credit card with a limit of at least $10,000 per month in order to directly charge to the
Company all business expenses incurred by her which are reasonable and necessary for Executive to perform her duties under
this Agreement in accordance with policies established from time to time by the Company.  All charges and
expenditures in excess of $500 shall be subject to pre-authorization by Company in accordance with Company policy and
procedures.

 

(b) Travel. Where
Executive is required to travel for Company, including but not limited to events, conferences and meetings related to the
Company, Company shall pay the costs of such travel which shall be pre-approved by the Board prior to incurring any
expense.

 

7. EXECUTIVE
BENEFITS.

 

(a)
Benefits. During the Employment Term, Executive shall be entitled to participate
in all group term insurance, disability insurance, health and medical insurance benefits, life insurance, retirement plans or programs
and any other employee benefits as are from time to time generally made available to executive employees of the Company pursuant
to the policies of the Company; provided that Executive shall be required to comply with the conditions attendant to coverage by
such employee benefit plans (collectively, “Benefit Plans”). The Board shall present any offerings for Benefit
Plans in writing to Executive when available. The Company may withhold from any benefits payable to Executive under any Benefit
Plans all federal, state, local and other taxes and amounts as shall be permitted or required to be withheld pursuant to any applicable
law, rule or regulation.

 

(b)
Vacation. Executive shall be entitled to four (4) weeks paid vacation per year
during the Employment Term. Vacation time shall be taken in accordance with the Company’s policies as may be established
from time to time by the Company for its executive staff.

 

(c)
Maternity Leave. To the extent that the Company does not have a maternity leave
policy in place for executive employees of the Company, Executive shall be entitled to eight (8) weeks of paid maternity leave
during the Employment Term. 

 

8. DEATH
AND DISABILITY.

 

(a)
Death. The Employment Term shall terminate on the date of Executive’s
death, in which event the Company shall, within 30 days of the date of death, pay to her estate, Executive’s Base Salary,
any unpaid Performance Bonus, Incentive Bonus or any other stock or bonus awards (including any bonus award for a plan
year that has ended prior to the time employment terminated where the award was scheduled to be paid after the date employment
terminated), reimbursable expenses and benefits owing to Executive through the date of Executive’s death together with any
benefits payable under any life insurance program in which Executive is a participant.   

 

(b)
Disability. The Employment Term shall terminate upon Executive’s Disability. For purposes of this Agreement,
“Disability” shall mean that Executive is unable to engage in any substantial gainful activity by reason of
any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for
a continuous period of not less than 12 months.  For purposes of determining Executive’s Disability, the Board
may rely on a determination by the Social Security Administration that Executive is totally disabled or a determination by the
Company’s disability insurance carrier that Executive has satisfied the above definition of Disability.  In case
of such termination, Executive shall be entitled to receive the Executive’s Base Salary, any unpaid Performance Bonus, Incentive
Bonus or any other stock or bonus awards (including any bonus award for a plan year that has ended prior to the time employment
terminated where the award was scheduled to be paid after the date employment terminated), reimbursable expenses and benefits
owing to Executive through the date of termination within 30 days of the date of the Company’s determination of Executive’s
Disability, together with any benefits payable under any disability insurance program in which Executive is a participant. Except
as otherwise contemplated by this Agreement, Executive will not be entitled to any other compensation upon termination of employment
pursuant to this subparagraph 8(b).

 

9. TERMINATION
OF EMPLOYMENT.

 

(a)
Termination With Cause By Company. The Company may terminate this Agreement
at any time during the Employment Term for Cause upon written notice to Executive, upon which termination shall be effective immediately.
For purposes of this Agreement, “Cause” means any one or more of the following: 

 

		i.	the commission of fraud by the Executive against the Company; 

 

		ii.	a material breach by Executive of any provision of this Agreement,
including the continued failure of Executive to perform the Services set forth in Section 3(a) of this Agreement, which breach
is not cured within thirty (30) days after receipt of written notice from the Company to Executive specifying the breach or, if
notice and cure have previously taken place regarding the same or a substantially similar breach, if the breach recurs; 

 

		iii.	Executive’s theft of funds or material property of the Company;
or

 

		iv.	Executive’s conviction of a felony, plea of guilty or nolo
contendere to a felony charge or any criminal act involving moral turpitude.

 

(b)
Termination Without Cause By Company. The Company may terminate this Agreement
at any time during the Employment Term without Cause upon ninety (90) days written notice to Executive. 

 

(c) Termination
Without Good Reason by Executive. Executive may terminate this Agreement at any time during the Employment Term
without Good Reason by providing the Company thirty (30) days’ written notice. 

 

(d) Termination
With Good Reason By Executive. Executive may terminate this Agreement at any time during the Employment Term with
Good Reason upon written notice to Company, upon which termination shall be effective immediately. For purposes of this
Agreement “Good Reason” means any one or more of the following:

 

		i.	material breach by the Company of any provision of this Agreement,
including without limitation, the Company’s failure to pay Executive any Base Salary, Performance Bonus or vested Incentive
Bonus, which such breach is not cured within thirty (30) days after receipt of written notice from Executive to the Company specifying
the breach or, if notice and cure have previously taken place regarding the same or a substantially similar breach, if the breach
recurs;

 

		ii.	a requirement by the Company that Executive change her primary work
location to a location that is more than thirty–five (35) miles from her then-existing main work location without Executive’s
consent to such change;

 

		iii.	the creation and continuation of a hostile work environment which
continues without corrective action being taken by the Company for a period of more than fifteen (15) days following written notice
by Executive to the Company identifying the nature and cause of such hostile work environment; or

 

		iv.	the Company, without Executive’s consent (A) changes Executive’s
title or position to a lower title or position, (B) reduces Executive’s current salary and/or benefits, or (C) assigns duties
or responsibilities to Executive that are materially inconsistent with her position.

 

(e)
Compensation upon Termination. 

 

		i.	In the event that the Company terminates the Executive’s employment
hereunder for Cause or the Executive terminates employment hereunder without Good Reason, the Executive shall be entitled to receive
the Executive’s Base Salary, any unpaid Performance Bonus, Incentive Bonus or any other vested stock or bonus awards, reimbursable
expenses and benefits owing to Executive (collectively, the “Accrued Amounts”) through the last day on which
Executive is actively employed by the Company under the terms of this Agreement (“Date of Termination”). The
Accrued Amounts shall be paid when required under applicable law and in any event within thirty (30) business days after the Date
of Termination.

 

		ii.	In the event that the Company terminates the Executive’s employment
hereunder without Cause or the Executive terminates employment hereunder with Good Reason, Executive shall be entitled to all Accrued
Amounts, which shall be paid when required under applicable law and in any event within thirty (30) business days after the Date
of Termination. In addition, the Company shall pay severance to Executive consisting of Executive’s Base Salary, payable
in accordance with normal payroll practices of the Company, and benefits under Benefit Plans (including health care as applicable),
for a period of twelve (12) months from the Date of Termination (the "Severance Period"). Except as otherwise
contemplated by this Agreement, Executive will not be entitled to any other compensation upon termination of this Agreement.

 

		iii.	The salary, applicable bonuses and fringe benefits to be paid to
Executive under Section 9(f)(ii) above during the Severance Period are referred to herein as the "Termination Compensation."
Executive shall not be entitled to any Termination Compensation unless: (1) Executive complies with the surviving restrictive covenants
set forth in Section 10 of this Agreement and (2) Executive executes and delivers to Company, on the Date of Termination, a release
in form and substance reasonably acceptable to Company and Executive, by which Executive releases Company from any obligations
and liabilities of any type whatsoever under this Agreement, except for Company's obligations with respect to the Termination Compensation.
For the avoidance of doubt, the release shall not affect (a) Executive’s right to indemnification, if any, for actions taken
within the scope of Executive’s employment with the Company or (b) any rights of Executive under the Asset Purchase Agreement.
Notwithstanding anything herein, no Termination Compensation shall be paid or otherwise provided to Executive until the applicable
revocation period related to the release has fully expired, not later than sixty (60) days from the Date of Termination, and the
release becomes fully and finally enforceable. The parties hereto acknowledge that the Termination Compensation to be provided
is in consideration for Executive’s release. 

 

		iv.	If Executive terminates this Agreement without Good Reason by providing
appropriate notice, the Company, at its election, may (1) require Executive to continue to perform duties hereunder for the full
notice period, or (2) terminate Executive's employment at any time during such notice period, provided that any such termination
shall not be deemed to be a termination without Cause of Executive's employment by the Company. Unless otherwise provided by Section
9(f), all compensation and benefits paid by Company to Executive under this Agreement shall cease upon the Date of Termination.

 

10. DISCLOSURE
OF TRADE SECRETS AND OTHER PROPRIETARY INFORMATION.

 

(a) Executive
acknowledges that she is prohibited from disclosing any confidential information about the Company, including but not limited
to trade secrets, formulas, processes, methods, plans, and financial information, to any party who is not a director, officer
or authorized agent of the Company or its subsidiaries and affiliates.  The Company will provide Executive with
valuable confidential information belonging to the Company or its subsidiaries or its affiliates above and beyond any
confidential information previously received by Executive and will associate Executive with the goodwill of the Company or
its subsidiaries or its affiliates above and beyond any prior association of Executive with that goodwill.  In
return, Executive promises never to disclose or misuse such confidential information and never to misuse such
goodwill. This Section 10(a) shall not apply to the extent that such confidential information of the Company is
generally available to and known by the public through no fault of Executive or if Executive is compelled to disclose
confidential information by judicial or administrative process or by other requirements of law.

 

(b) Executive will not,
during the Employment Term, directly or indirectly, as an executive, employer, consultant, agent, principal, partner,
manager, stockholder, officer, director, or in any other individual or representative capacity, engage in or participate in
any other business for her own account or for or on behalf of another person, firm, or corporation that is competitive with,
conflicts, or interferes with the Company’s Business or Executive’s performance of duties under this Agreement,
except those permitted business obligations of Executive as set forth in Exhibit B hereto or those that may otherwise
be pre-approved by the Company. Notwithstanding the foregoing, Executive may own, directly or indirectly, solely as an
investment, securities of any company traded on any national securities exchange if Executive does not, directly or
indirectly, own 5% or more of any class of securities of such company.

 

(c) Executive
will not, during the Employment Term and for a period of one (1) year thereafter, directly or indirectly, work in Arizona as
an employee, employer, consultant, agent, principal, partner, manager, stockholder, officer, director, or in any other
individual or representative capacity for any person or entity who is competitive with the Business of the Company, except
for those permitted business obligations of Executive as set forth in Exhibit B hereto or those that may otherwise be
pre-approved by the Company. Notwithstanding the foregoing, Executive may own, directly or indirectly, solely as an
investment, securities of any company traded on any national securities exchange if Executive does not, directly or
indirectly, own 5% or more of any class of securities of such company. For the avoidance of doubt, Executive is also a party
to that certain Non-Competition Agreement of even date herewith in favor of AZDP on the terms set forth therein.

 

(d) Executive will not,
during the Employment Term and for a period of one (1) year thereafter, on her behalf or on behalf of any other business
enterprise, directly or indirectly, under any circumstance other than at the direction and for the benefit of the Company,
(i) solicit for employment or hire any person employed by the Company or any of its subsidiaries, or (ii) call on, solicit,
or take away any person or entity who was a customer of the Company or any of its subsidiaries or affiliates during
Executive’s employment with the Company, in either case for a business that is competitive with the Business of the
Company.

 

(e) It
is expressly agreed by Executive that the nature and scope of each of the provisions set forth above are reasonable and
necessary. If, for any reason, any aspect of the above provisions as it applies to Executive is determined by a court of
competent jurisdiction to be unreasonable or unenforceable under applicable law, the provisions shall be modified to the
extent required to make the provisions enforceable.  Executive acknowledges and agrees that her services are of
unique character and expressly grants to the Company or any subsidiary or affiliate of the Company or any successor of any of
them, the right to enforce the above provisions through the use of all remedies available at law or in equity, including, but
not limited to, injunctive relief.

 

11. COMPANY
PROPERTY.

 

(a) Any
patents, inventions, discoveries, applications, processes, models or financial statements designed, devised, planned,
applied, created, discovered or invented by Executive during the Employment Term, regardless of when reduced to writing or
practice, which pertain to any aspect of the Company’s or its subsidiaries’ or affiliates’ Business shall
be the sole and absolute property of the Company, and Executive shall promptly report the same to the Company and promptly
execute any and all documents that may from time to time be reasonably be requested by the Company to assure the Company the
full and complete ownership thereof.

 

(b) All
records, files, lists, including computer generated lists, drawings, documents, equipment and similar items relating to the
Company’s Business which Executive shall prepare or receive from the Company shall remain the Company’s sole and
exclusive property. Upon termination of this Agreement, Executive shall promptly return to the Company all property of the
Company in her possession. Executive further represents that she will not copy or cause to be copied, print out or cause to
be printed out any software, documents or other materials originating with or belonging to the Company except as needed to
perform the Services under this Agreement. Executive additionally represents that, upon termination of her employment with
the Company, she will not retain in her possession any such software, documents or other materials.

 

12. EQUITABLE
RELIEF.  It is mutually understood and agreed that Executive’s services are special, unique, unusual,
extraordinary and of an intellectual character giving them a peculiar value, the loss of which cannot be reasonably or
adequately compensated in damages in an action at law. Accordingly, in the event of any breach of this Agreement by
Executive, including, but not limited to, the breach of any of the provisions of paragraphs 10 or 11 hereof, the Company
shall be entitled to equitable relief by way of injunction or otherwise in addition to any damages which the Company may be
entitled to recover.

 

13. CONSENT TO
JURISDICTION AND VENUE; ARBITRATION.   The Executive hereby consents and agrees that the State of Arizona
shall have personal jurisdiction and proper venue with respect to any dispute between the Executive and the Company. In any
dispute with the Company, the Executive will not raise, and hereby expressly waives, any objection or defense to any such
jurisdiction as an inconvenient forum. Executive and the Company agree that all disputes and claims of any nature that
Executive may have against the Company including all statutory, contractual, and common law claims (including all employment
discrimination claims), and all other disputes and claims of any nature that the Company may have against Executive, shall be
settled by binding arbitration in accordance with the commercial arbitration rules then in effect of the American Arbitration
Association, as set forth in the Asset Purchase Agreement, Section 8.10.

 

14. NOTICE.  Any
notice, request, demand or other communication permitted or required to be given under this Agreement shall be in writing
and shall be given in accordance with the notice provisions set forth in the Asset Purchase Agreement, Section 8.02.

 

15. INTERPRETATION;
HEADINGS.  The parties acknowledge and agree that the terms and provisions of this Agreement have been
negotiated, shall be construed fairly as to all parties hereto, and shall not be construed in favor of or against any party.
The paragraph headings contained in this Agreement are for reference purposes only and shall not affect the meaning or
interpretation of this Agreement.

 

16. SUCCESSORS
AND ASSIGNS; ASSIGNMENT; INTENDED BENEFICIARIES.  Neither this Agreement, nor any of Executive’s
rights, powers, duties or obligations hereunder, may be assigned by Executive. This Agreement shall be binding upon and inure
to the benefit of Executive and her heirs and legal representatives and the Company and its successors. Successors of the
Company shall include, without limitation, any corporation or corporations acquiring, directly or indirectly, all or
substantially all of the assets of the Company, whether by merger, consolidation, purchase, lease or otherwise, and such
successor shall thereafter be deemed “the Company” for the purpose hereof.

 

17. NO WAIVER
BY ACTION.  Any waiver or consent from the Company respecting any term or provision of this Agreement or
any other aspect of the Executive’s conduct or employment shall be effective only in the specific instance and for the
specific purpose for which given and shall not be deemed, regardless of frequency given, to be a further or continuing waiver
or consent. The failure or delay of the Company at any time or times to require performance of, or to exercise any of its
powers, rights or remedies with respect to, any term or provision of this Agreement or any other aspect of the
Executive’s conduct or employment in no manner (except as otherwise expressly provided herein) shall affect the
Company’s right at a later time to enforce any such term or provision.

 

18. COUNTERPARTS;
GOVERNING LAW; AMENDMENTS.  This Agreement may be executed in two counterpart copies, each of which may be
executed by one of the parties hereto, but all of which, when taken together, shall constitute a single agreement binding
upon all of the parties hereto. This Agreement and all other aspects of the Executive’s employment shall be governed by
and construed in accordance with the applicable laws pertaining in the State of Delaware (other than those that would defer
to the substantive laws of another jurisdiction). Each and every modification and amendment of this Agreement shall be in
writing and signed by the parties hereto, and any waiver of, or consent to any departure from, any term or provision of this
Agreement shall be in writing and signed by each affected party hereto.  

 

20. Severability.

If any provision
of this Agreement shall be held by a court or arbitrator to be invalid, unenforceable, or void, such provision shall be enforced
to the fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event
that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum
time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall reduce the time period
or scope to the maximum time period or scope permitted by law.

21. ENTIRE
AGREEMENT.  The entire understanding and agreement between the Parties has been incorporated into this
Agreement, and this Agreement supersedes all other agreements and understandings between Executive and the Company with
respect to the relationship of Executive with the Company or its affiliates or subsidiaries.

 

22. EXECUTIVE
AcknowledgEment

EXECUTIVE ACKNOWLEDGES
THAT EXECUTIVE HAS HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL CONCERNING THIS AGREEMENT, THAT EXECUTIVE HAS READ AND UNDERSTANDS
THE AGREEMENT, IS FULLY AWARE OF ITS LEGAL EFFECT, AND THAT EXECUTIVE HAS ENTERED INTO IT FREELY BASED ON EXECUTIVE’S OWN
JUDGMENT AND NOT ON ANY REPRESENTATIONS OR PROMISES OTHER THAN THOSE CONTAINED IN THIS AGREEMENT. 

 

 

 

[Signature page follows.]

    	 

    	 

    

 

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Executive Employment Agreement as of the date set forth above.

 

 

	(“COMPANY”)	(“EXECUTIVE”)
	Item 9 Labs Corp.	 
	 	 
	 	 
	_____________________________	_____________________________
	By:  Bryce Skalla	By: Sara Gullickson
	Its: Chief Executive Officer	 

 

 

    	 

    	 

    

 

EXHIBIT A

DESCRIPTION OF EMPLOYMENT SERVICES

 

 

As the Chief Executive Officer (“CEO”)
of Item 9 Labs Corp. (the “Company”), the CEO shall report to the board of directors (the “Board”)
and is responsible for leading the development and execution of the Company’s long term strategy with a view to creating
shareholder value. The CEO’s leadership role also entails being ultimately responsible for all day-to-day management decisions
and for implementing the Company’s long and short term plans. The CEO acts as a direct liaison between the Board and management
of the Company and communicates to the Board on behalf of management. Specifically, the duties of the CEO shall include:

 

Strategy & Planning

		·	Drafting / Execution of Short Term Execution of National Expansion
Plan

		o	Submission of Applications (Dispensary Permits.com Team to Execute)– Markets TBD –
See 09-20-18 - DP - Our Brands Page - v3- Page 9 for Markets with Opportunities in 2019.

		o	Selection of Distressed Cannabis Assets for INLB Acquisition, specifically, Licensees: Cultivation,
MM Product Lines & Dispensary – Markets TBD (Based on bullet above).

 

Financial Planning & Budgets

		·	Create Budget with Jeffrey Rassas for Expansion, Acquisition and
INLB Operations.

		·	Assist, as required, in raising additional capital at appropriate
valuations to enable the Company to meet sales, growth and market share objectives.

 

 

SEC and OTC Filings

		·	Assist in the preparation, review, and filing of all interim, quarterly,
and annual reports and other filings necessary for OTC and SEC compliance.

 

Investor Relations Management

		·	Manage and interface with investors for general relations outreach
and response, as necessary, and attend local and national conferences to promote the Company generally.

 

Management & Execution

		·	Ensure Vice President(s) of Southwest, Midwest, East Coast, and Southern
Regions for Expansion are executing National Expansion Strategy though Application, Acquisition, and Operations mentioned above.

		·	Ensure Cultivation, Processing, and Dispensary Department Heads Meet
Revenue Milestones & Expansion Milestones

		o	SOPS

		o	R&D

		o	Training

		o	Sales

 

Company Leadership/Vision

		·	Employee / Management Staffing Plan

		o	Build Organizational Chart & Ensure Chart Includes Examples Below:

 
Chief Financial Officer

 
Chief Operating Officer

  Chief Compliance Officer

 
Medical Advisory Board

 
Director of Community

 
Dispensary / Retail Manager

 
Director of Security

 
Director of Technology

 
Director of Extraction

  Director
of Patient Services

 
Director of Cultivation

 
Human Resources

 
Banking Relations

 
Real Estate Advisor /Firm for Expansion

 
Architect/ Engineer(S)

 
Director of Marketing

 
Legal / Attorney

 
Insurance

 
Director of Staffing

		·	Roles, Responsibilities & Expectations 

		·	Selection, Hiring, Retainment and Termination Policies & Procedures

    	 

    	 

    

 

EXHIBIT B

Pre-existing
business obligations of Executive 

		·	Strive Wellness of Nevada, LLC

		·	Strive Management, LLC 

		·	North Dakota – WE- Mend d/b/a Strive Life Dispensary 

		·	West Hollywood – November 2018: Dispensary 10, LLC

		o	Sara Gullickson owns 33% ownership

		·	Nevada (Retail) – December 2019- Strive Wellness of Nevada,
LLC 

		o	Sara Gullickson, Larry Lemons & Donnie Burton control the license
if it is awarded.  Local partner collectively has 13% of the facility.

		·	Ohio – December 2018 Strive Wellness of Ohio, LLC 

		o	Sara Gullickson, Larry Lemons & Donnie Burton control the license
if it is awarded. 

		·	New Jersey – January 2019 Modern Remedies, LLC 

		o	Sara Gullickson has 2% ownership and facility will be Strive Model
if license is awarded. 

		·	Michigan, Benton Harbor – February 2019 The Harvest Foundation,
LLC

		o	Sara Gullickson, Larry Lemons & Donnie Burton control the license
if it is awarded.Exhibit

Exhibit 4.2

FIFTH AMENDED AND RESTATED REGISTRATION AGREEMENT
THIS FIFTH AMENDED AND RESTATED REGISTRATION AGREEMENT is made as of February 6, 2019 by and among Health Catalyst, Inc., a Delaware corporation (the “Company”) and the Persons listed on the Schedule of Investors attached hereto (each, an “Investor” and collectively, the “Investors”).
WHEREAS, the Company and certain of the Investors are parties to a Series F Stock Purchase Agreement of even date herewith (the “Stock Purchase Agreement”), pursuant to which, among other things, certain of the Investors shall purchase shares of the Company’s newly authorized Series F Preferred stock, par value $0.001 per share (the “Series F Preferred”);
WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred stock, par value $0.001 per share (the “Series A Preferred”), Series B Preferred stock, par value $0.001 per share (the “Series B Preferred”), Series C Preferred stock, par value $0.001 per share (the “Series C Preferred”), Series D Preferred stock, par value $0.001 per share (the “Series D Preferred”), and Series E Preferred stock, par value $0.001 per share (the “Series E Preferred” and with the Series A Preferred, the Series B Preferred, the Series C Preferred, the Series D Preferred, and the Series F Preferred, the “Preferred Stock”), and possess registration rights pursuant to a Fourth Amended and Restated Registration Agreement, dated as of February 9, 2016, by and among the Company and the Existing Investors (the “Old Registration Agreement”);
WHEREAS, the Existing Investors are holders of a majority of the Investor Registrable Securities (as defined in the Old Registration Agreement), and desire to amend and restate the Old Registration Agreement in its entirety to, among other things, add the new Investors as parties; and WHEREAS, the execution and delivery of this Agreement is a condition to Closing under the Stock Purchase Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree as follows:
Section 1.    Demand Registrations.
(a)    Requests for Registration.  Subject to the terms and conditions of this Agreement, at any time 180 days after the Company has completed a public offering of its Common Stock under the Securities Act (an “IPO”), the holders of Investor Registrable Securities may request registration under the Securities Act of all or any portion of their Investor Registrable Securities on Form S-1 or any similar long-form registration (“Long-Form Registrations”), and the holders of Investor Registrable Securities may request registration under the Securities Act of all or any portion of their Investor Registrable Securities on Form S-3 (including pursuant to Rule 415 under the Securities Act) or any similar short- form registration (“Short-Form Registrations”) if available.  All registrations requested pursuant to this Section 1(a) are referred to herein as “Demand Registrations.” Each request for a Demand Registration shall specify the approximate number of Investor Registrable Securities requested to be registered, the anticipated per share price range for such offering and the intended method of distribution.  Within ten days after receipt of any such request, the Company shall give written notice of such requested registration to all other holders of Investor Registrable Securities and, subject to the terms of Section 1(d) hereof, shall include in such registration (and in all related registrations and qualifications under state blue sky laws or in compliance with other registration requirements and in any related underwriting) all Investor Registrable Securities with respect to which the Company has received written requests for inclusion therein within fifteen (15) days after the receipt of the Company’s notice.

(b)    Long-Form Registrations.  The holders of Investor Registrable Securities shall be entitled to request two (2) Long-Form Registrations in which the Company shall pay all Registration Expenses (“Company-paid Long-Form Registrations”); provided that the aggregate offering value of the Investor Registrable Securities requested to be registered in any Long-Form Registration must equal at least $20,000,000.  A registration shall not count as one of the permitted Long-Form Registrations until it has become effective, and neither the last or any subsequent Company-paid Long-Form Registration shall count as one of the permitted Long-Form Registrations unless the holders of Investor Registrable Securities are able to register and sell at least 75% of Investor Registrable Securities requested to be included in such registration; provided that in any event the Company shall pay all Registration Expenses in connection with any registration initiated as a Company-paid Long-Form Registration whether or not it has become effective and whether or not such registration has counted as one of the permitted Company- paid Long-Form Registrations.
(c)    Short-Form Registrations.  In addition to the Long-Form Registrations provided pursuant to Section 1(b), the holders of Investor Registrable Securities shall be entitled to request an unlimited number of Short-Form Registrations in which the Company shall pay all Registration Expenses; provided that the aggregate offering value of the Investor Registrable Securities requested to be registered in any Short-Form Registration must equal at least $5,000,000.  Demand Registrations shall be Short- Form Registrations whenever the Company is permitted to use any applicable short form and if the managing underwriters (if any) agree to the use of a Short-Form Registration.  After the Company has become subject to the reporting requirements of the Exchange Act, the Company shall use its reasonable best efforts to make Short-Form Registrations on Form S-3 available for the sale of Investor Registrable Securities.  If the Company is qualified to and, pursuant to the request of the holders of a majority of the Investor Registrable Securities, has filed with the Securities and Exchange Commission a registration statement under the Securities Act on Form S-3 pursuant to Rule 415 (the “Shelf Registration”), then the Company shall use its reasonable best efforts to cause the Shelf Registration to be declared effective under the Securities Act as soon as practicable after filing, and once effective, the Company shall cause such Shelf Registration to remain effective for a period ending on the earlier of (i) the date on which all Investor Registrable Securities included in such registration have been sold pursuant to the Shelf Registration or (ii) the date as of which all of the Investor Registrable Securities included in such registration are able to be sold within a 90-day period in compliance with Rule 144 under the Securities Act.  Notwithstanding the foregoing, the holders of Investor Registrable Securities may have their shares of Investor Registrable Securities fully excluded from the Piggyback Registration upon the managing underwriters’ advice if the Piggyback Registration is the Company’s IPO.
(d)    Priority on Demand Registrations.  The Company shall not include in any Demand Registration any securities which are not Investor Registrable Securities without the prior written consent of the holders of a majority of the Investor Registrable Securities included in such registration, unless 100% of the Investor Registrable Securities requested to be included in such registration are so included.  If a Demand Registration is an underwritten offering and the managing underwriters or placement agent advise the Company in writing that in their opinion the number of Investor Registrable Securities and, if permitted hereunder, other securities requested to be included in such offering exceeds the number of Investor Registrable Securities and other securities, if any, which can be sold therein without adversely affecting the marketability of the offering, in an orderly manner in such offering within a price range acceptable to the holders of a majority of the Investor Registrable Securities initially requesting registration, the Company shall include in such registration prior to the inclusion of any securities which are not Investor Registrable Securities the number of Investor Registrable Securities requested to be included which, in the opinion of such underwriters can be sold, without adversely affecting the marketability of the offering in an orderly manner within the price range of such offering, pro rata among the respective holders thereof on the basis 

2

of the amount of Investor Registrable Securities owned by each such holder.  Any Persons other than holders of Investor Registrable Securities who participate in Demand Registrations which are not at the Company’s expense must pay their share of the Registration Expenses as provided in Section 5 hereof.
(e)    Restrictions.  The Company shall not be obligated to effect any Demand Registration within 180 days after the effective date of a previous Long-Form Registration that is a Demand Registration.  The Company may postpone for up to 180 days the filing or the effectiveness of a registration statement for a Demand Registration or may cause a registration statement for a Demand Registration to cease to be effective if the Company determines that such Demand Registration would reasonably be expected to have a material adverse effect on any proposal or plan by the Company or any of its subsidiaries to engage in any financing, sale, acquisition of assets or stock (other than in the ordinary course of business); any merger, consolidation, tender offer, recapitalization, reorganization or similar transaction or require the Company to disclose any material nonpublic information which would reasonably be likely to be detrimental to the Company and its subsidiaries; or render the Company unable to comply with the requirements under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; provided that in such event, the holders of Investor Registrable Securities initially requesting such Demand Registration shall be entitled to withdraw such request and, if such request is withdrawn, such Demand Registration shall not count as one of the permitted Demand Registrations hereunder and the Company shall pay all Registration Expenses in connection with such registration.  The Company may delay a Demand Registration hereunder only once in any twelve-month period.
(f)    Selection of Underwriters.  The holders of a majority of the Investor Registrable Securities initially requesting registration hereunder shall have the right to select the investment banker(s) and manager(s) to administer the offering, subject to the Company’s approval which shall not be unreasonably withheld or delayed so long as such investment banker(s) and manager(s) are of recognized national standing.
(g)    Other Registration Rights.  The Company represents and warrants that it is not a party to, or otherwise subject to, any other agreement granting registration rights to any other Person with respect to any securities of the Company.  Except as provided in this Agreement, the Company shall not grant to any Persons the right to request the Company to register any equity securities of the Company, or any securities, options or rights convertible or exchangeable into or exercisable for such securities, without the prior written consent of the holders of a majority of the Investor Registrable Securities.
Section 2.    Piggyback Registrations.
(a)    Right to Piggyback.  Whenever the Company proposes to register any of its securities under the Securities Act (other than (i) pursuant to a Demand Registration, (ii) in connection with registrations on Form S-4 or S-8 promulgated by the Securities and Exchange Commission or any successor forms, (iii) a registration relating solely to employment benefit plans, or (iv) in connection with the IPO) and the registration form to be used may be used for the registration of Investor Registrable Securities (a “Piggyback Registration”), the Company shall give prompt written notice to all holders of Investor Registrable Securities of its intention to effect such a registration and, subject to the terms of Section 2(c) and Section 2(d) hereof, shall include in such registration (and in all related registrations or qualifications under blue sky laws or in compliance with other registration requirements and in any related underwriting) all Investor Registrable Securities with respect to which the Company has received written requests for inclusion therein within twenty (20) days after the receipt of the Company’s notice.
(b)    Piggyback Expenses.  The Registration Expenses of the holders of Investor Registrable Securities shall be paid by the Company in all Piggyback Registrations.

3

(c)    Priority on Primary Registrations.  If a Piggyback Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the number which can be sold in such offering without adversely affecting the marketability of the offering, the Company shall include in such registration (i) first, the securities the Company proposes to sell, (ii) second, any Investor Registrable Securities requested to be included in such registration, pro rata among the holders of such Investor Registrable Securities on the basis of the number of Investor Registrable Securities owned by each such holder, and (iii) third, other securities requested to be included in such registration.
(d)    Priority on Secondary Registrations.  If a Piggyback Registration is an underwritten secondary registration on behalf of holders of the Company’s securities, and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the number which can be sold in such offering without adversely affecting the marketability of the offering, the Company shall include in such registration (i) first, the securities requested to be included therein by the holders requesting such registration and the Investor Registrable Securities requested to be included in such registration, pro rata among the holders of such securities on the basis of the number of securities so requested to be included therein owned by each such holder, and (ii) second, other securities requested to be included in such registration.
(e)    Selection of Underwriters.  If any Piggyback Registration is an underwritten offering, the selection of investment banker(s) and manager(s) for the offering must be approved by the holders of a majority of the Investor Registrable Securities included in such Piggyback Registration.  Such approval shall not be unreasonably withheld or delayed.
(f)    Other Registrations.  If the Company has previously filed a registration statement with respect to Investor Registrable Securities pursuant to Section 1 or pursuant to this Section 2, and if such previous registration has not been withdrawn or abandoned, the Company shall not file or cause to be effected any other registration of any of its equity securities or securities convertible or exchangeable into or exercisable for its equity securities under the Securities Act (except on Form S-8 or any successor form), whether on its own behalf or at the request of any holder or holders of such securities, until a period of at least 90 days has elapsed from the effective date of such previous registration.
(g)    Obligations of Seller.  During such time as any holder of Investor Registrable Securities may be engaged in a distribution of securities pursuant to an underwritten Piggyback Registration, such holder shall distribute such securities only under the registration statement and solely in the manner described in the registration statement.
Section 3.    Holdback Agreements.
(a)    No holder of Investor Registrable Securities shall (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any equity securities of the Company or any securities convertible into or exercisable or exchangeable (directly or indirectly) for equity securities of the Company (whether such shares or any such securities are then owned by such holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise, from the date on which the Company gives notice to the holders of Investor Registrable Securities that a preliminary prospectus has been circulated for the IPO to the date that is 180 

4

days following the date of the final prospectus for such IPO (the “IPO Holdback Period”), except as part of such IPO.  Notwithstanding the foregoing, this Section 3(a) shall not be applicable to or otherwise be binding on the holders of Investor Registrable Securities unless the Company complies with its obligations under Section 3(b) below in connection with any such offering.  The IPO Holdback Period shall also be extended as may be requested by the Company or an underwriter to accommodate regulatory restrictions on the publication or other distribution of research reports and analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto).  The extension in the immediately preceding sentence is referred to herein as the “Holdback Extension.”  The Company may impose stop-transfer instructions with respect to the shares of its common stock (or other securities) subject to the foregoing restriction during any IPO Holdback Period or any period of Holdback Extension.  Each holder of Investor Registrable Securities agrees to execute a Holdback Agreement in customary form as may be requested by any underwriter pursuant to any Holdback Period under this Section 3.
(b)    The Company (i) shall not effect any public sale or distribution of its equity securities, or any securities convertible into or exchangeable or exercisable for such securities, during the IPO Holdback Period (including during any period of Holdback Extension) (except as part of such underwritten registration or pursuant to registrations on Form S-8 or any successor form), unless the underwriters managing the registered public offering otherwise agree in writing, and (ii) shall cause each officer, director and holder (other than the Investors) of at least 1% (on a fully-diluted basis) of its Common Stock, or any securities convertible into or exchangeable or exercisable for Common Stock, purchased from the Company at any time after the date of this Agreement (other than in a registered public offering), to agree not to effect any public sale or distribution (including sales pursuant to Rule 144 under the Securities Act) of any such securities during such periods (except as part of such underwritten registration, if otherwise permitted), unless the underwriters managing the registered public offering otherwise agree in writing.
Section 4.    Registration Procedures.  Whenever the holders of Investor Registrable Securities have requested that any Investor Registrable Securities be registered pursuant to this Agreement, the Company shall use its commercially reasonable best efforts to effect the registration and the sale of such Investor Registrable Securities in accordance with the intended method of disposition thereof, and pursuant thereto the Company shall as expeditiously as possible:
(a)    in accordance with the Securities Act and all applicable rules and regulations promulgated thereunder, prepare and file with the Securities and Exchange Commission a registration statement, and all amendments and supplements thereto and related prospectuses, with respect to such Investor Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective (provided that before filing a registration statement or prospectus or any amendments or supplements thereto, the Company shall furnish to the counsel selected by the holders of a majority of the Investor Registrable Securities covered by such registration statement copies of all such documents proposed to be filed, which documents shall be subject to the review and comment of each such counsel), and include in any Short-Form Registration such additional information reasonably requested by a majority of the Investor Registrable Securities registered under the applicable registration statement, or the underwriters, if any, for marketing purposes, whether or not required by applicable securities laws;
(b)    notify in writing each holder of Investor Registrable Securities to be sold thereunder of the effectiveness of each registration statement filed hereunder and prepare and file with the Securities and Exchange Commission such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for a period of not less than 180 days and comply with the provisions of the Securities Act with respect to 

5

the disposition of all securities covered by such registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in such registration statement;
(c)    furnish to each seller of Investor Registrable Securities thereunder such number of copies of such registration statement, each amendment and supplement thereto, the prospectus included in such registration statement (including each preliminary prospectus), each Free Writing Prospectus and such other documents as such seller may reasonably request in order to facilitate the disposition of the Investor Registrable Securities owned by such seller;
(d)    use its commercially reasonable best efforts to register or qualify such Investor Registrable Securities under such other securities or blue sky laws of such jurisdictions as any seller reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable such seller to consummate the disposition in such jurisdictions of the Investor Registrable Securities owned by such seller (provided that the Company shall not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this subparagraph or (ii) consent to general service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction);
(e)    notify in writing each seller of such Investor Registrable Securities, (i) promptly after it receives notice thereof, of the date and time when such registration statement and each post- effective amendment thereto has become effective or a prospectus or supplement to any prospectus relating to a registration statement has been filed and when any registration or qualification has become effective under a state securities or blue sky law or any exemption thereunder has been obtained, (ii) promptly after receipt thereof, of any request by the Securities and Exchange Commission for the amendment or supplementing of such registration statement or prospectus or for additional information, and (iii) at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading, and, at the request of any such seller, the Company shall prepare a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Investor Registrable Securities, such prospectus shall not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading;
(f)    prepare and file promptly with the Securities and Exchange Commission, and notify such holders of Investor Registrable Securities prior to the filing of, such amendments or supplements to such registration statement or prospectus as may be necessary to correct any statements or omissions if, at the time when a prospectus relating to such securities is required to be delivered under the Securities Act, when any event has occurred as the result of which any such prospectus or any other prospectus as then in effect would include an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and, in case any of such holders of Investor Registrable Securities or any underwriter for any such holders is required to deliver a prospectus at a time when the prospectus then in circulation is not in compliance with the Securities Act or the rules and regulations promulgated thereunder, the Company shall use its commercially reasonable efforts to prepare promptly upon request of any such holder or underwriter such amendments or supplements to such registration statement and prospectus as may be necessary in order for such prospectus to comply with the requirements of the Securities Act and such rules and regulations;
(g)    cause all such Investor Registrable Securities to be listed on each securities exchange on which similar securities issued by the Company are then listed;

6

(h)    provide a transfer agent and registrar for all such Investor Registrable Securities not later than the effective date of such registration statement;
(i)    enter into and perform such customary agreements (including underwriting agreements in customary form) and take all such other actions as the holders of a majority of the Investor Registrable Securities being sold or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of such Investor Registrable Securities (including, without limitation, participation in “road shows,” investor presentations and marketing events and effecting a stock split or a combination of shares);
(j)    make available for inspection by any seller of Investor Registrable Securities, any underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other agent retained by any such seller or underwriter, all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, directors, employees and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration statement;
(k)    take all commercially reasonable actions to ensure that any Free-Writing Prospectus utilized in connection with any Demand Registration or Piggyback Registration hereunder complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to the extent required thereby and, when taken together with the related prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading;
(l)    otherwise use its commercially reasonable best efforts to comply with all applicable rules and regulations of the Securities and Exchange Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve months beginning with the first day of the Company’s first full calendar quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder;
(m)    permit any holder of Investor Registrable Securities which holder, in its good faith judgment (based on the advice of counsel), could reasonably be expected to be deemed to be an underwriter or a controlling person of the Company, to participate in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in writing, which in the reasonable judgment of such holder and its counsel should be included;
(n)    use its commercially reasonable best efforts to prevent the issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending or preventing the use of any related prospectus or suspending the qualification of any equity securities included in such registration statement for sale in any jurisdiction, and in the event of the issuance of any such stop order or other such order the Company shall advise such holders of Investor Registrable Securities of such stop order or other such order promptly after it shall receive notice or obtain knowledge thereof and shall use its commercially reasonable efforts promptly to obtain the withdrawal of such order;
(o)    use its commercially reasonable best efforts to cause such Investor Registrable Securities covered by such registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the sellers thereof to consummate the disposition of such Investor Registrable Securities;

7

(p)    obtain a cold comfort letter from the Company’s independent public accountants in customary form and covering such matters of the type customarily covered by cold comfort letters as the holders of a majority of the Investor Registrable Securities being sold reasonably request (provided that such Investor Registrable Securities constitute at least 10% of the securities covered by such registration statement); and
(q)    provide a legal opinion of the Company’s outside counsel, dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, dated the date of the closing under the underwriting agreement), with respect to the registration statement, each amendment and supplement thereto, the prospectus included therein (including the preliminary prospectus) and such other documents relating thereto in customary form and covering such matters of the type customarily covered by legal opinions of such nature.
Section 5.    Registration Expenses.
(a)    All expenses incident to the Company’s performance of or compliance with this Agreement, including without limitation all registration, qualification and filing fees, fees and expenses of compliance with securities or blue sky laws, printing expenses, messenger and delivery expenses, fees and disbursements of custodians, and fees and disbursements of counsel for the Company and all independent certified public accountants, underwriters (excluding underwriting discounts and commissions) and other Persons retained by the Company (all such expenses being herein called “Registration Expenses”), shall be borne by the Company as provided in this Agreement, except that the Company shall, in any event, pay its internal expenses (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing the securities to be registered on each securities exchange on which similar securities issued by the Company are then listed.  Each Person that sells securities pursuant to a Demand Registration or Piggyback Registration hereunder shall bear and pay all underwriting discounts and commissions applicable to the securities sold for such Person’s account.  The Company shall not be required to pay for any Registration Expenses begun pursuant to Section 1 if the registration request is subsequently withdrawn at the request of the holders of a majority of the Investor Registrable Securities to be registered (in which case all such holders shall bear such expenses pro rata based upon the number of Investor Registrable Securities that were to be included in the withdrawn registration), unless the holders of a majority of the Investor Registrable Securities agree to forfeit their right to one registration pursuant to Subsection 1(b), provided, however, that if, at the time of such withdrawal, such holders have learned of a material change in the condition, business, or prospects of the Company from that known to the holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then such holders shall not be required to pay any of the Registration Expenses and shall not forfeit their right to a registration pursuant to Subsection 1(b).
(b)    In connection with each Demand Registration and each Piggyback Registration, the Company shall reimburse the holders of Investor Registrable Securities included in such registration for the reasonable fees and disbursements of one counsel chosen by the holders of a majority of the Investor Registrable Securities included in such registration, such fees not to exceed $10,000.
Section 6.    Indemnification.
(a)    The Company agrees to indemnify, to the extent permitted by law, each holder of Investor Registrable Securities, its officers, directors, members, partners, agents, affiliates and employees and each Person who controls such holder (within the meaning of the Securities Act) against all losses, 

8

claims, actions, damages, liabilities and expenses caused by any of the following statements, omissions or violations by the Company:  (i) any untrue or alleged untrue statement of material fact contained in any registration statement, prospectus, preliminary prospectus or Free-Writing Prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, or (ii) any violation or alleged violation by the Company of the Securities Act or any other similar federal or state securities laws or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any such registration, qualification or compliance, and to pay to each holder of Investor Registrable Securities, its officers and directors and each Person who controls such holder (within the meaning of the Securities Act), as incurred, any legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability or action, except insofar as the same are caused by or contained in any information furnished in writing to the Company by such holder expressly for use therein.  In connection with an underwritten offering, the Company shall indemnify such underwriters, their officers and directors and each Person who controls such underwriters (within the meaning of the Securities Act) to the same extent as provided above with respect to the indemnification of the holders of Investor Registrable Securities.
(b)    In connection with any registration statement in which a holder of Investor Registrable Securities is participating, each such holder shall furnish to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such registration statement or prospectus and, to the extent permitted by law, shall indemnify the Company, its directors and officers and each Person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses resulting from any untrue or alleged untrue statement of material fact contained in the registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information or affidavit so furnished in writing by such holder expressly for use therein; provided that the obligation to indemnify shall be individual, not joint and several, for each holder and shall be limited to the net amount of proceeds received by such holder from the sale of Investor Registrable Securities pursuant to such registration statement.
(c)    Any Person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any Person’s right to indemnification hereunder to the extent such failure has not materially prejudiced the indemnifying party) and (ii) unless in such indemnified party’s reasonable judgment after consulting with legal counsel a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party.  If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent shall not be unreasonably withheld, conditioned or delayed).  An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party after consulting with legal counsel a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim.  In such instance, the conflicting indemnified parties shall have a right to retain one separate counsel, chosen by the holders of a majority of the Investor Registrable Securities included in the registration, at the expense of the indemnifying party.  No indemnifying party, in the defense of such claim or litigation, shall, except with the consent of each indemnified party, consent to the entry of any judgment or enter into any settlement which does not include as an unconditional 

9

term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.
(d)    If the indemnification provided for in this Section 6 is held by a court of competent jurisdiction to be unavailable to an indemnified party or is otherwise unenforceable with respect to any loss, claim, damage, liability or action referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amounts paid or payable by such indemnified party as a result of such loss, claim, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other hand in connection with the statements or omissions which resulted in such loss, claim, damage, liability or action as well as any other relevant equitable considerations; provided that the maximum amount of liability in respect of such contribution shall be limited, in the case of each seller of Investor Registrable Securities, to an amount equal to the net proceeds actually received by such seller from the sale of Investor Registrable Securities effected pursuant to such registration.  The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.  The parties hereto agree that it would not be just or equitable if the contribution pursuant to this Section 6(d) were to be determined by pro rata allocation or by any other method of allocation that does not take into account such equitable considerations.  The amount paid or payable by an indemnified party as a result of the losses, claims, damages, liabilities or expenses referred to herein shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any action or claim which is the subject hereof.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who is not guilty of such fraudulent misrepresentation.
(e)    The indemnification and contribution provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party or any officer, director or controlling Person of such indemnified party and shall survive the transfer of securities.
(f)    No indemnifying party shall, except with the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement that does not include as an unconditional term thereof giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.
Section 7.    Participation in Underwritten Registrations.  No Person may participate in any registration hereunder which is underwritten unless such Person (i) agrees to sell such Person’s securities on the basis provided in any underwriting arrangements approved by the Person or Persons entitled hereunder to approve such arrangements (including pursuant to any over-allotment or “green shoe” option requested by the underwriters, provided that no holder of Investor Registrable Securities shall be required to sell more than the number of Investor Registrable Securities such holder has requested to include) and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements; provided that no holder of Investor Registrable Securities included in any underwritten registration shall be required to make any representations or warranties to the Company or the underwriters (other than representations and warranties regarding such holder and such holder’s intended method of distribution) or to undertake any indemnification obligations to the Company or the underwriters with respect thereto, except as otherwise specifically provided in Section 6 

10

hereof or to agree to any lockup or holdback restrictions, except as specifically provided in Section 3(a) hereof.  Each holder of Investor Registrable Securities agrees to execute and deliver such other agreements as may be reasonably requested by the Company and the lead managing underwriter(s) that are consistent with such holder’s obligations under Section 3 or that are necessary to give further effect thereto.
Section 8.    Definitions.
(a)    “Common Stock” means the Common Stock, par value $0.001 per share, of the Company.
(b)    “Free Writing Prospectus” means a free-writing prospectus, as defined in Rule 405 of the Securities Act.
(c)    “Investor Registrable Securities” means (i) any Common Stock issued or issuable upon the conversion of any Preferred Stock (ii) any Common Stock issued or issuable with respect to the securities referred to in clause (i) above by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization, and (iii) any other shares of Common Stock held by Persons holding securities described in clauses (i) and (ii) above.  As to any particular Investor Registrable Securities, such securities shall cease to be Investor Registrable Securities upon the earliest to occur of (v)(i) a liquidation, dissolution or winding up of the Company or (ii) a Fundamental Change (as defined in the Company’s Certificate of Incorporation), (w) they have been distributed to the public pursuant to an offering registered under the Securities Act, (x) they are sold to the public through a broker, dealer or market maker in compliance with Rule 144 under the Securities Act (or any similar rule then in force), (y) after the Company has completed an Initial Public Offering they are eligible to be sold without limitation pursuant to Rule 144 under the Securities Act (or any similar rule then in force) or (z) they are repurchased by the Company or any subsidiary of the Company.  For purposes of this Agreement, a Person shall be deemed to be a holder of Investor Registrable Securities, and the Investor Registrable Securities shall be deemed to be in existence, whenever such Person has the right to acquire directly or indirectly such Investor Registrable Securities (upon conversion or exercise in connection with a transfer of securities or otherwise, but disregarding any restrictions or limitations upon the exercise of such right), whether or not such acquisition has actually been effected, and such Person shall be entitled to exercise the rights of a holder of Investor Registrable Securities hereunder.
(d)    “Preferred Stock” has the meaning set forth in the recitals hereto.
(e)    Unless otherwise stated, other capitalized terms contained herein have the meanings set forth in the Stock Purchase Agreement.
Section 9.    Miscellaneous.
(a)    No Inconsistent Agreements.  The Company shall not hereafter enter into any agreement with respect to its securities which is inconsistent with or violates the rights granted to the holders of Investor Registrable Securities in this Agreement.
(b)    Adjustments Affecting Investor Registrable Securities.  The Company shall not intentionally take any action, or permit any change to occur, with respect to its securities which would adversely affect the ability of the holders of Investor Registrable Securities to include such Investor Registrable Securities in a registration undertaken pursuant to this Agreement or which would adversely affect the marketability of such Investor Registrable Securities in any such registration (including, without limitation, effecting a stock split or a combination of shares).

11

(c)    Remedies.  Any Person having rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages caused by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law.  The parties hereto agree and acknowledge that money damages would not be an adequate remedy for any breach of the provisions of this Agreement and that, in addition to any other rights and remedies existing in its favor, any party shall be entitled to specific performance and/or other injunctive relief from any court of law or equity of competent jurisdiction (without posting any bond or other security) in order to enforce or prevent violation of the provisions of this Agreement.
(d)    Amendments and Waivers.  Except as otherwise provided herein, the provisions of this Agreement may be amended or waived only upon the prior written consent of the Company and holders of a majority of the Investor Registrable Securities; provided, that if an amendment would treat an Investor in a materially disproportionate and adverse manner relative to the other Investors, then the amendment shall also require the consent of such Investor so adversely treated.  The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms.
(e)    Successors and Assigns.  All covenants and agreements in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not.  In addition, whether or not any express assignment has been made, the provisions of this Agreement which are for the benefit of purchasers or holders of Investor Registrable Securities are also for the benefit of, and enforceable by, any subsequent holder of Investor Registrable Securities; provided that if any holder of Investor Registrable Securities which is a limited partnership or limited liability company distributes any Investor Registrable Securities to its partners or members after the Company has effected a registered public offering of the Common Stock under the Securities Act, such transferees of Investor Registrable Securities shall no longer be subject to the provisions of Section 3(a) hereof.
(f)    Amendment of Old Registration Agreement; Complete Agreement.  The Old Registration Agreement is hereby amended and restated in its entirety by this Agreement and the provisions of the Old Registration Agreement shall no longer be of any force or effect.  This Agreement (including the schedules hereto) and the other agreements and instruments referred to herein contain the complete agreement between the parties hereto with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements and representations by or between the parties hereto (whether written or oral) which may have related to the subject matter hereto or thereof in any way (including, without limitation, the Old Registration Agreement).
(g)    Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.
(h)    Counterparts.  This Agreement may be executed simultaneously in two or more counterparts (including by means of facsimile signature pages), any one of which need not contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same Agreement.

12

(i)    Descriptive Headings.  The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.
(j)    Governing Law.  The corporate law of the State of Delaware shall govern all issues and questions concerning the relative rights of the Company and its stockholders.  All other issues and questions concerning the construction, validity, interpretation and enforcement of this Agreement and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.  In furtherance of the foregoing, the internal law of the State of Delaware shall control the interpretation and construction of this Agreement (and all schedules and exhibits hereto), even though under that jurisdiction’s choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily apply.
(k)    Notices.  All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (i) when delivered personally to the recipient, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day; provided that such notice under this clause (ii) shall not be effective unless within one business day of the notice a copy of such notice is dispatched to the recipient by first class mail, return receipt requested, or reputable overnight courier service (charges prepaid), (iii) one business day after it is sent to the recipient by reputable overnight courier service (charges prepaid) or (iv) five days after it is mailed to the recipient by first class mail, return receipt requested.  Such notices, demands and other communications shall be sent to the Company at the address specified below, to any holder of Investor Registrable Securities as of the date hereof to the address set forth on the applicable Schedules hereto and to any other party subject to this Agreement at such address as indicated by the Company’s records, or at such address or to the attention of such other Person as the recipient party has specified by prior written notice to the sending party.  Any party may change its address for receipt of notice by providing sending prior written notice of the change to the sending party.
The Company:
Health Catalyst, Inc.
3165 East Millrock Drive, Suite 450
Salt Lake City, UT 84121
		
	Attention:
	Dan Orenstein

		
	Telephone:
	801-708-6800

		
	Fax:
	801-365-0076

		
	Email:
	dan.orenstein@healthcatalyst.com

or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party.
(l)    Mutual Waiver of Jury Trial.  As a specifically bargained inducement for each of the parties to enter into this Agreement (with each party having had opportunity to consult counsel), each party hereto expressly and irrevocably waives the right to trial by jury in any lawsuit or legal proceeding relating to or arising in any way from this Agreement or the transactions contemplated herein, and any lawsuit or legal proceeding relating to or arising in any way to this Agreement or the transactions contemplated herein shall be tried in a court of competent jurisdiction by a judge sitting without a jury.

13

(m)    Additional Investors.  Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder.  No action or consent by the Investors shall be required for such joinder to this Agreement by such additional investor, so long as such additional investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.
[Signature Page Follows]

14

IN WITNESS WHEREOF, the parties have executed this Registration Agreement as of the date first written above.
	
		
	HEALTH CATALYST, INC

	 
	 

	By:
	/s/ Daniel D. Burton

	Name:
	Daniel D. Burton

	Title:
	Chief Executive Officer

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS:

	 
	 

	SEQUOIA CAPITAL U.S. GROWTH FUND IV, L.P.

	SEQUOIA CAPITAL USGF PRINCIPALS FUND IV, L.P.

	 
	 

	By:
	SCGF IV Management, L.P., a Cayman Islands exempted limited partnership, General Partner of Each

	 
	 

	By:
	SC US (TTGP), LTD., a Cayman Islands limited liability company

	 
	 

	Its:
	General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Managing Director

	 
	 

	SC US GF V HOLDINGS, LTD.

	a Cayman Islands exempted company

	 
	 

	By:  Sequoia Capital U.S. Growth Fund V, L.P. and Sequoia Capital USGF Principals Fund V, L.P., both Cayman Islands Exempted Limited Partnerships, its Members

	 
	 

	By:  SCGF V Management, L.P.,

	a Cayman Islands Exempted company, its General Partner

	 
	 

	By:  SC US (TTGP), LTD.,

	a Cayman Islands Exempted Limited Partnership, its General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Director

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	SEQUOIA CAPITAL U.S. GROWTH FUND V, L.P.

	a Cayman Islands exempted limited partnership

	 
	 

	By:
	SCGF V MANAGEMENT, L.P.,

	a Cayman Islands exempted limited partnership, its General Partner

	 
	 

	By:
	SC US (TTGP), LTD.,

	a Cayman Islands exempted company, its General Partner

	 
	 

	By:
	/s/ Mike Dixon

	Name:
	Mike Dixon

	Title:
	Director

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	NORWEST VENTURE PARTNERS XI, LP

	 
	 

	By:
	Genesis VC Partners XI, LLC

	Its:
	General Partner

	 
	 

	By:
	NVP Associates, LLC

	Its:
	Managing Member

	 
	 

	By:
	/s/ Promod Haque

	Name:
	Promod Haque

	Its:
	 

	 
	 

	NORWEST VENTURE PARTNERS XII, LP

	 
	 

	By:
	Genesis VC Partners XI, LLC

	Its:
	General Partner

	 
	 

	By:
	NVP Associates, LLC

	Its:
	Managing Member

	 
	 

	By:
	/s/ Promod Haque

	Name:
	Promod Haque

	Its:
	 

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	HQC ACQUISITION, LLC

	 
	 

	By:
	/s/ Fraser Bullock

	Name:
	Fraser Bullock

	Title:
	President

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	KAISER PERMANENTE VENTURES, LLC - SERIES A

	 
	 

	By:
	/s/ Thomas Meier

	Name:
	Thomas Meier

	Title:
	SVP & Treasurer

	 
	 

	KAISER PERMANENTE VENTURES, LLC - SERIES B

	 
	 

	By:
	/s/ Chris Grant

	Name:
	Chris Grant

	Title:
	Member, Managing Committee

	 
	 

	THE PERMANENTE FEDERATION LLC - SERIES J

	 
	 

	By:
	/s/ Anne Cadwell

	Name:
	Anne Cadwell

	Title:
	CFO

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	CHV FUND II, LLC

	 
	 

	By:
	CHV Fund II Management, LLC

	Its:
	Manager

	 
	 

	By:
	/s/ John D. Huesing

	Name:
	John D. Huesing

	Its:
	Authorized Representative

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND, L.P.

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, L.P.

	Its:
	General Partner

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, LLC

	Its:
	General Partner

	 
	 

	By:
	/s/ Jonathan Goodman

	Name:
	Jonathan Goodman

	Title:
	General Counsel

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC2, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC3, L.P.

	 
	 

	SANDS CAPITAL PRIVATE GROWTH FUND-HC4, L.P.

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, L.P., its general partner

	 
	 

	By:
	Sands Capital Private Growth Fund-GP, LLC, its general partner

	 
	 

	By:
	/s/ Jonathan Goodman

	Name:
	Jonathan Goodman

	Title:
	General Counsel

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	TENAYA CAPITAL VI, LP

	 
	 

	By:
	Tenaya Capital VI GP, LLC, its General Partner

	 
	 

	By:
	/s/ Dorian Merritt

	Name:
	Dorian Merritt

	Its:
	Attorney-In-Fact

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	ZIONS SBIC LLC

	 
	 

	By:
	/s/ Kent Madsen

	Name:
	Kent Madsen

	Its:
	Manager

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	BRIGHAM YOUNG UNIVERSITY,

	a Utah nonprofit corporation

	 
	 

	By:
	/s/ G P Williams

	Name:
	G P Williams

	Title:
	Faculty Advisor

Cougar Capital contact information:
Brigham Young University,
a Utah nonprofit corporation
c/o Cougar Capital Program
David Paul – Treasurer
A-153 ASB
Provo, UT 84602
Email:  davidwpaul@byu.edu
Phone:  801-422-4887

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	UNIVERSITY GROWTH FUND I, L.P.

	 
	 

	By:
	UGFIGP,LLC

	Its:
	General Partner

	 
	 

	By:
	/s/ Tom Stringham

	Name:
	Tom Stringham

	Its:
	Manager

	 
	 

	By:
	/s/ Peter Harris

	Name:
	Peter Harris

	Its:
	Manager

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	UPMC

	 
	 

	By:
	/s/ C. Talbot Heppenstall, Jr.

	Name:
	C. Talbot Heppenstall, Jr.

	Its:
	Treasurer

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	OSF HEALTHCARE SYSTEM,

	an Illinois not for profit corporation

	 
	 

	By:
	/s/ Robert C. Sehring

	Name:
	Robert C. Sehring

	Its:
	Chief Executive Officer

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ John A. Kane

	John A. Kane

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	JOHN MUIR HEALTH

	 
	 

	By:
	/s/ Chris Pass

	Name:
	Chris Pass

	Its:
	Chief Financial Officer

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	IOWA HEALTH SYSTEM D/B/A UNITYPOINT HEALTH

	 
	 

	By:
	/s/ Matthew Kirschner

	Name:
	Matthew Kirschner

	Title:
	Vice President, Treasury

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
		
	INVESTORS (CONTINUED):

	 
	 

	ORBIMED ROYALTY OPPORTUNITIES II, LP

	 
	 

	By OrbiMed Advisors LLC,

	its investment manager

	 
	 

	By:
	/s/ W. Carter Neild

	Name:
	W. Carter Neild

	Its:
	Member

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ Brent C. James

	Brent C. James

[Signature Page to Fifth Amended and Restated Registration Agreement]

	
	
	INVESTORS (CONTINUED):

	 

	/s/ W. David Hemingway

	W. David Hemingway

[Signature Page to Fifth Amended and Restated Registration Agreement]

SCHEDULE I
SCHEDULE OF INVESTORS
	
			
	Investor:
	Notice Address:
	With a copy to (which shall not constitute notice to such Investor):

	Sequoia Capital U.S. Growth Fund V, L.P.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	SC US GF V Holdings, LTD.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Sequoia Capital USGF Principals Fund IV, L.P.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Sequoia Capital U.S. Growth Fund IV, L.P.
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
Attention:  Michael Dixon
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Norwest Venture Partners XI, LP
	525 University Avenue, Suite 800
Palo Alto, CA 94301
Attention:  Promod Haque and William Myers
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Norwest Venture Partners XII, LP
	525 University Avenue, Suite 800
Palo Alto, CA 94301
Attention:  Promod Haque and William Myers
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	HQC Acquisition,
LLC
	c/o Sorenson Capital
3400 Ashton Blvd., Suite 400
Lehi, UT 84043
Telephone:  (801) 407-8444
Telecopy:  (801) 407-8410
Attention:  Fraser Bullock
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Matoaka, LLC
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

Schedule of Investors to the Fifth Amended and Restated Registration Agreement

	
			
	Todd Cozzens
	c/o Sequoia Capital
2800 Sand Hill Road, Suite 101
Menlo Park, CA 94025
Telephone:  (650) 854-3927
Telecopy:  (650) 854-2977
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Kaiser Permanente Ventures, LLC - Series A
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	Kaiser Permanente Ventures, LLC - Series B
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	The Permanente Federation LLC - Series J
	Sam E. Brasch
One Kaiser Plaza, 22nd Floor
Oakland, CA 94612
	 

	CHV Fund II, LLC
	340 W. 10th Street, Suite 2100
Indianapolis, IN 46202
Attention:  John D. Huesint
Telephone:  (317) 963-1310
	 

	Partners HealthCare System, Inc.
	101 Huntington Avenue, 4th Floor
Boston, MA 02199
Attn:  Roger Kitterman
Telephone:  (617) 954-9500
Fax:  (917) 954-9356
	 

	Sands Capital Private Growth Fund, L.P.
	Jonathan Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth Fund-HC, L.P.
	Jonathan Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth Fund-HC2, L.P.
	Jonathan P. Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth Fund-HC3, L.P.
	Jonathan P. Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Sands Capital Private Growth Fund-HC4, L.P
	Jonathan P. Goodman, General Counsel
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone:  703-562-5293
Email:  jgoodman@sandscap.com
	 

	Allina Health System
	2925 Chicago Avenue
Minneapolis, MN 55407
Telephone:  (612) 262-5403
Facsimile:  (612) 262-4264
Attention:  General Counsel
	Faegre Baker Daniels LLP
2200 Wells Fargo Center
90 South Seventh Street
Minneapolis, MN 55402-3901
Telephone:  (612) 766-7790
Telecopy:  (612) 554-6467
Attention:  Mark D. Pihlstrom

Schedule of Investors to the Fifth Amended and Restated Registration Agreement

	
			
	Tenaya Capital
VI, LP
	c/o Tenaya Capital, LLC
3280 Alpine Road
Portola Valley, CA 94028
Phone:  650-687-6500
Attn:  Stewart Gollmer and Dave Markland
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Zions SBIC LLC
	15 West South Temple #500
Salt Lake City, UT 84111
Attn:  Kent Madsen
	Kirkland & Ellis LLP
3330 Hillview Avenue
Palo Alto, CA 94304
Telephone:  (650) 859-7050
Telecopy:  (650) 859-7500
Attention:  Adam D. Phillips

	Leavitt Equity Partners I, L.P.
	299 S. Main Street, Suite 2300
Salt Lake City, UT 84111
Attn:  Taylor Leavitt
	 

	Brigham Young University (Cougar Capital)
	Brigham Young University,
a Utah nonprofit corporation
c/o Cougar Capital Program
David Paul – Treasurer
A-153 ASB
Provo, UT 84602
Email:  davidwpaul@byu.edu
Phone:  801-422-4887
	 

	University Growth Fund I, L.P.
	University Growth Fund
299 South Main, Suite 357
Salt Lake City, UT 84111
Attn:  Tom Stringham
	 

	UPMC
	UPMC
U.S. Steel Tower, Suite 6071
600 Grant Street
Pittsburgh, PA 15219
Attn: Senior Associate Counsel and
Vice President
	 

	OSF Healthcare
System
	Attn: Robert C. Sehring, CEO
800 NE Glen Oak Avenue
Peoria, IL 61603.
Fax:  309-655-6869
	 

	Leerink Capital Investors I L.P.
	One Federal Street
Boston, MA 02110
Attn:  Todd Cozzens
	 

	Leerink Transformation Fund I L.P.
	One Federal Street, 25th Floor
Boston, MA 02110
Attn:  Todd Cozzens
Phone:  (617) 918-4821
Fax:  (617) 918-4921
todd@LTPequity.com
	 

	MultiCare Health System
	MultiCare Health System
737 S. Fawcett Ave.
MS: 737-4-CFO
Tacoma, WA 98402
Attn:  Judy Swain
Phone:  253.459.8003
Fax:  253.459.7854
Judy.swain@multicare.org
	 

	John A. Kane
	18242 Via Caprini Drive
Ft Myers, FL 33913
Fax:  239-689-8187
Cell:  802-999-6769
Email jackakane@gmail.com
	 

Schedule of Investors to the Fifth Amended and Restated Registration Agreement

	
			
	John Muir Health
	1450 Treat Blvd Suite #350
Walnut Creek, CA 94597
Attn:  Ravi Hundal M.D. or
Taejoon Ahn M.D. MPH CPE
Taejoon. Ahn_MD@johnmuirhealth.com
	1400 Treat Boulevard
Walnut Creek, CA 94597
Attn:  General Counsel
Phone:  925-941-2217
Fax:  925-952-2979
max.reynolds@johnmuirhealth.com

	John Muir Medical Group, Inc.
	1400 Treat Boulevard
Walnut Creek, CA 94597
Attn:  Chris Pass, CFO
Phone:  (925) 941-2622
Fax:  (925) 952-2979
chris.pass@johnmuirhealth.com
	 

	Omkara LLC
	Omkara LLC
c/o Anita Pramoda
6085 West Twain Ave., Suite 101
Las Vegas, NV 89103
	 

	Ben Fatto Limited Partnership
	Ben Fatto Limited Partnership
Attn: Broc C. Hiatt and Craig D. Cardon
1223 S. Clearview Ave., Suite 103
Mesa, AZ 85209
bhiatt@cardonhiatt.com
	 

	3M Company
	3M Ventures
3M Company
3M Center, Building 220-9E-02
St. Paul, MN 55144-1000
bdwright2@mmm.com
	 

	Iowa Health System D/B/A UnityPoint Health
	UnityPoint Health
1776 West Lakes Parkway, Suite 400
West Des Moines, IA 50266-8239
matthew.kirschner@unitypoint.org
	 

	Aetna Inc.
	Aetna Inc.
151 Farmington Avenue, RC6A
Hartford, CT 06156
Attention:  General Counsel
Fax:  (860) 273-8430
	Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, NY 10017
Attention:  H. Oliver Smith
And Harold Birnbaum
Fax:  (212) 701-5800

	OrbiMed Royalty Opportunities II, LP
	601 Lexington Avenue, 54th Floor
New York, NY 10022
Attn:  Mark Jelley
jelleym@orbimed.com
cc:  ROSCreditOps@OrbiMed.com
Telephone:  (212) 739-6461
	Covington & Burling LLP
The New York Times Building, 620
Eighth Avenue
New York, NY 10018-1405
Attn: Peter Schwartz

	Brent C. James
	4 E. Knightsbridge Lane
Salt Lake City, UT 84103-2241
Brent.james@qualityscience.pro
	 

	W David Hemingway
	1212 Canyon Oaks Way
Salt Lake City, UT 84103
wdavid.hemingway@gmail.com
	 

Schedule of Investors to the Fifth Amended and Restated Registration Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]